US stem cell royalty entitlement row stirring
This article was originally published in Clinica
A dispute is brewing in California over royalty payments on future stem cell discoveries. A research group affiliated to the University of Wisconsin said it will demand licence fees and payments for any work that emerges from the stem cell institute set up by the state of California.
You may also be interested in...
GNC hires Josh Burris as chief US officer; Clasado BioSciences adds Bellchambers as commercial director; and Barentz plans expansion with Cinven investment.
The House passage of a Democratic bill authorizing the federal government to negotiate drug prices in Medicare has sharpened the debate over how prices feed innovation, but the underlying policy stands little chance of being enacted without a Democratic wave in the next election. Pink Sheet's table highlights the key provisions of HR 3 and other pending pricing legislation.